Real-world evidence: new opportunities for osteoporosis research. Recommendations from a Working Group from the European Society for Clinical and Economic Aspects of Osteoporosis, Osteoarthritis and Musculoskeletal Diseases (ESCEO).

Drug effectiveness Epidemiology Fracture Osteoporosis Real-world evidence Registry

Journal

Osteoporosis international : a journal established as result of cooperation between the European Foundation for Osteoporosis and the National Osteoporosis Foundation of the USA
ISSN: 1433-2965
Titre abrégé: Osteoporos Int
Pays: England
ID NLM: 9100105

Informations de publication

Date de publication:
Aug 2023
Historique:
received: 03 03 2023
accepted: 28 04 2023
medline: 31 7 2023
pubmed: 23 6 2023
entrez: 23 6 2023
Statut: ppublish

Résumé

This narrative review summarises the recommendations of a Working Group of the European Society for Clinical and Economic Aspects of Osteoporosis, Osteoarthritis and Musculoskeletal Diseases (ESCEO) for the conduct and reporting of real-world evidence studies with a focus on osteoporosis research. Vast amounts of data are routinely generated at every healthcare contact and activity, and there is increasing recognition that these real-world data can be analysed to generate scientific evidence. Real-world evidence (RWE) is increasingly used to delineate the natural history of disease, assess real-life drug effectiveness, understand adverse events and in health economic analysis. The aim of this work was to understand the benefits and limitations of this type of data and outline approaches to ensure that transparent and high-quality evidence is generated. A ESCEO Working Group was convened in December 2022 to discuss the applicability of RWE to osteoporosis research and approaches to best practice. This narrative review summarises the agreed recommendations for the conduct and reporting of RWE studies with a focus on osteoporosis research. It is imperative that research using real-world data is conducted to the highest standards with close attention to limitations and biases of these data, and with transparency at all stages of study design, data acquisition and curation, analysis and reporting to increase the trustworthiness of RWE study findings.

Identifiants

pubmed: 37351614
doi: 10.1007/s00198-023-06827-2
pii: 10.1007/s00198-023-06827-2
pmc: PMC10382414
doi:

Types de publication

Review Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

1283-1299

Informations de copyright

© 2023. The Author(s).

Références

Clin Pharmacol Ther. 2022 Jan;111(1):90-97
pubmed: 34689339
Lancet. 2020 Oct 10;396(10257):1056
pubmed: 32950071
Ther Innov Regul Sci. 2022 Jan;56(1):137-144
pubmed: 34633649
N Engl J Med. 2004 Sep 16;351(12):1250-1
pubmed: 15356289
J Bone Miner Res. 2021 May;36(5):820-832
pubmed: 33373491
Osteoporos Int. 2019 Jan;30(1):45-57
pubmed: 30382319
Circulation. 2021 Mar 9;143(10):1002-1013
pubmed: 33327727
Arch Osteoporos. 2021 Jun 2;16(1):82
pubmed: 34080059
Best Pract Res Clin Rheumatol. 2022 Sep;36(3):101766
pubmed: 35961836
Clin Epidemiol. 2012;4:303-13
pubmed: 23204870
Pharmacoepidemiol Drug Saf. 2020 Dec;29(12):1616-1626
pubmed: 32894794
Osteoporos Int. 2017 Apr;28(4):1355-1363
pubmed: 28058444
Ther Innov Regul Sci. 2022 Sep;56(5):795-804
pubmed: 35680722
Bone. 2016 Apr;85:9-14
pubmed: 26802259
Osteoporos Int. 2022 May;33(5):1155-1164
pubmed: 35032187
Arch Osteoporos. 2022 Aug 31;17(1):119
pubmed: 36044096
Osteoporos Int. 2017 Oct;28(10):2997-3004
pubmed: 28714038
Bone. 2022 Jan;154:116255
pubmed: 34763115
Pharmacoepidemiol Drug Saf. 2000 Sep;9(5):359-66
pubmed: 19025840
Osteoporos Int. 2022 Sep;33(9):1837-1844
pubmed: 35578134
J Bone Miner Res. 2012 Oct;27(10):2208-16
pubmed: 22623101
Calcif Tissue Int. 2016 Sep;99(3):243-9
pubmed: 27099132
Clin Pharmacol Ther. 2022 Jan;111(1):122-134
pubmed: 34716990
Arch Osteoporos. 2022 Jun 28;17(1):87
pubmed: 35763133
Osteoporos Int. 2018 Jun;29(6):1227-1242
pubmed: 29460102
PLoS Med. 2015 Oct 06;12(10):e1001885
pubmed: 26440803
Osteoporos Int. 2021 Apr;32(4):645-651
pubmed: 33151378
JBMR Plus. 2022 Aug 14;6(9):e10665
pubmed: 36111201
N Engl J Med. 2009 Aug 20;361(8):756-65
pubmed: 19671655
Rheum Dis Clin North Am. 2019 May;45(2):173-186
pubmed: 30952391
Osteoporos Int. 2020 Mar;31(3):485-492
pubmed: 31832693
Clin Pharmacol Ther. 2022 Jan;111(1):135-144
pubmed: 34726771
JAMA. 2016 Nov 1;316(17):1818-1819
pubmed: 27802529
Med Care. 2009 Jan;47(1):69-72
pubmed: 19106733
Bone. 2016 Jun;87:19-26
pubmed: 26968752
Osteoporos Int. 2015 Sep;26(9):2243-8
pubmed: 26018089
J Am Geriatr Soc. 2017 Mar;65(3):490-495
pubmed: 28304090
Arch Osteoporos. 2020 Aug 20;15(1):133
pubmed: 32816151
BMJ. 2009 Jun 29;338:b2393
pubmed: 19564179
Health Technol Assess. 2021 Mar;25(17):1-106
pubmed: 33739919
Clin Pharmacol Ther. 2022 Jan;111(1):21-23
pubmed: 34797920
Reumatol Clin (Engl Ed). 2019 Sep - Oct;15(5):e1-e4
pubmed: 29195740
J Clin Epidemiol. 2005 Apr;58(4):323-37
pubmed: 15862718
Clin Epidemiol. 2015 Nov 17;7:449-90
pubmed: 26604824
J Bone Miner Res. 2007 Mar;22(3):465-75
pubmed: 17144789
Osteoporos Int. 2020 Aug;31(8):1499-1506
pubmed: 32239237
Osteoporos Int. 2022 Oct;33(10):2205-2216
pubmed: 35779100
Drug Saf. 2022 Aug;45(8):815-837
pubmed: 35895225
Inform Prim Care. 2011;19(3):135-45
pubmed: 22688222
BMJ. 2018 Nov 14;363:k3532
pubmed: 30429167
Expert Rev Pharmacoecon Outcomes Res. 2012 Apr;12(2):159-66
pubmed: 22458617
Lancet Diabetes Endocrinol. 2022 Apr;10(4):273-283
pubmed: 35247315
J Bone Miner Res. 2021 Feb;36(2):244-251
pubmed: 32990990
J Clin Epidemiol. 1992 Jul;45(7):703-14
pubmed: 1619449
Pharmacoeconomics. 2021 Feb;39(2):181-209
pubmed: 33026634
Hypertension. 2023 Jan;80(1):182-191
pubmed: 36330805
Clin Epidemiol. 2018 Oct 09;10:1417-1431
pubmed: 30349390
JAMA. 1998 Dec 23-30;280(24):2077-82
pubmed: 9875874
Int J Epidemiol. 2021 Jul 9;50(3):987-999
pubmed: 33367629
Lancet. 2020 Jun 13;395(10240):1820
pubmed: 32511943
Front Pharmacol. 2022 Oct 19;13:1017391
pubmed: 36339548
Front Endocrinol (Lausanne). 2021 Aug 31;12:702261
pubmed: 34531824
Osteoporos Int. 2022 Aug;33(8):1703-1714
pubmed: 35524068
BMJ. 2020 Nov 4;371:m3919
pubmed: 33148619
Clin Pharmacol Ther. 2023 Jan;113(1):135-151
pubmed: 36254408
Am J Epidemiol. 2008 Aug 1;168(3):329-35
pubmed: 18515793

Auteurs

Rebecca J Moon (RJ)

MRC Lifecourse Epidemiology Centre, University of Southampton, Southampton, SO16 6YD, UK.
Paediatric Endocrinology, University Hospital Southampton NHS Foundation Trust, Southampton, UK.

Jean-Yves Reginster (JY)

WHO Collaborating Center for Epidemiology of Musculoskeletal Health and Ageing, Liège, Belgium.
Division of Epidemiology, Public Health and Health Economics, University of Liège, Liège, Belgium.

Nasser M Al-Daghri (NM)

Biochemistry Department, College of Science, King Saud University, Riyadh, Saudi Arabia.

Jotheeswaran A Thiyagarajan (JA)

Ageing and Health Unit, World Health Organisation, Geneva, Switzerland.

Charlotte Beaudart (C)

WHO Collaborating Center for Epidemiology of Musculoskeletal Health and Ageing, Liège, Belgium.
Division of Epidemiology, Public Health and Health Economics, University of Liège, Liège, Belgium.

Olivier Bruyère (O)

WHO Collaborating Center for Epidemiology of Musculoskeletal Health and Ageing, Liège, Belgium.
Division of Epidemiology, Public Health and Health Economics, University of Liège, Liège, Belgium.

Nansa Burlet (N)

Division of Epidemiology, Public Health and Health Economics, University of Liège, Liège, Belgium.

Manju Chandran (M)

Osteoporosis and Bone Metabolism Unit, Department of Endocrinology, Singapore General Hospital, Singapore, Singapore.

Mario Coelho da Silva (MC)

Laboratory of Clinical and Therapeutical Pharmacology, Lisbon, Portugal.

Philip G Conaghan (PG)

Leeds Institute of Rheumatic and Musculoskeletal Medicine, University of Leeds, Leeds, UK.
NIHR Leeds Musculoskeletal Biomedical Research Unit, Leeds, UK.

Willard H Dere (WH)

Department of Internal Medicine, Utah Center for Clinical and Translational Science, University of Utah School of Medicine, Salt Lake City, UT, USA.

Adolfo Diez-Perez (A)

Department of Internal Medicine, Hospital del Mar-IMIM, Autonomous University of Barcelona and CIBERFES, Instituto Carlos III, Barcelona, Spain.

Peyman Hadji (P)

Frankfurt Centre for Bone Health, Frankfurt, Germany.
Philipps University of Marburg, Hesse, Germany.

Philippe Halbout (P)

International Osteoporosis Foundation, Nyon, Switzerland.

Mickaël Hiligsmann (M)

Department of Health Services Research, CAPHRI Care and Public Health Research Institute, Maastricht University, Maastricht, the Netherlands.

John A Kanis (JA)

Mary McKillop Institute for Health Research, Australian Catholic University, Melbourne, Australia.
Centre for Metabolic Bone Diseases, University of Sheffield, Sheffield, UK.

Eugene V McCloskey (EV)

MRC Versus Arthritis Centre for Integrated Research in Musculoskeletal Ageing, University of Sheffield, Sheffield, UK.
Mellanby Centre for Musculoskeletal Research, Department of Oncology & Metabolism, University of Sheffield, Sheffield, UK.

Sif Ormarsdottir (S)

Icelandic Medicines Agency, Reykjavik, Iceland.

Daniel Prieto-Alhambra (D)

Pharmaco- and Device Epidemiology, Centre for Statistics in Medicine, Nuffield Department of Orthopaedics, Rheumatology and Musculoskeletal Sciences (NDORMS), University of Oxford, Oxford, UK.

Régis P Radermecker (RP)

Department of Clinical Pharmacology, Diabetes, Nutrition and Metabolic Disorders, CHU Liege, Liege, Belgium.

René Rizzoli (R)

Geneva University Hospitals and Faculty of Medicine, Geneva, Switzerland.

Yousef Al-Saleh (Y)

College of Medicine, King Saud Bin Abdulaziz University for Health Sciences, Riyadh, Saudi Arabia.
King Abdullah International Medical Research Center, Riyadh, Saudi Arabia.
Department of Medicine, King Abdulaziz Medical City, Riyadh, Ministry of National Guard-Health Affairs, Riyadh, Saudi Arabia.

Stuart L Silverman (SL)

Cedars Sinai Medical Center, Los Angeles, USA.

Lee S Simon (LS)

SDG LLC, Cambridge, MA, USA.

Friederike Thomasius (F)

Frankfurt Centre for Bone Health, Frankfurt, Germany.

Tjeerd van Staa (T)

Centre for Health Informatics, University of Manchester, Manchester, UK.

Andrea Laslop (A)

Scientific Office, Austrian Medicines and Medical Devices Agency, Vienna, Austria.

Cyrus Cooper (C)

MRC Lifecourse Epidemiology Centre, University of Southampton, Southampton, SO16 6YD, UK.
NIHR Southampton Biomedical Research Centre, University of Southampton and University Hospital Southampton NHS Foundation Trust, Southampton, UK.
National Institute for Health Research (NIHR) Musculoskeletal Biomedical Research Centre, University of Oxford, Oxford, UK.

Nicholas C Harvey (NC)

MRC Lifecourse Epidemiology Centre, University of Southampton, Southampton, SO16 6YD, UK. nch@mrc.soton.ac.uk.
NIHR Southampton Biomedical Research Centre, University of Southampton and University Hospital Southampton NHS Foundation Trust, Southampton, UK. nch@mrc.soton.ac.uk.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH